Please replace the CROSS-REFERENCE SECTION TO RELATED

APPLICATIONS beginning on page 1, line 4, with the following rewritten paragraphs:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/229,

365, filed August 30, 2000, which is incorporated herein by reference in its entirety for all

purposes.

Related subject matter is described in co-owned U.S. Application No.

09/944,163, filed August 30, 2001, which claims the benefit of U.S. Provisional Application

No. 60/228,974, filed August 30, 2000; and in U.S. Provisional Patent Application No.

60/316,386, filed August 30, 2001, and in U.S. Application No. 09/944,051, filed August 30,

2001, which claims the benefit of U.S. Provisional Patent Application No. 60/229,191 filed

August 30, 2000, the disclosures of each of the foregoing applications being incorporated

herein by reference in their entirety for all purposes.

Please replace the paragraph beginning at page 9, line 25 with the following

rewritten paragraph:

The term "UL33" or "human UL33" refers to open reading frame 33 of the

unique long region of the genome of human strains of CMV and proteins encoded by this reading

frame. The nucleotide and amino acid sequences for an exemplary UL33 are set forth in SEQ ID

NOS:19 and 20, respectively. The term also includes various splice variants. For example, the

term can include the splice variant having the nucleotide and amino acid sequences of SEQ ID

NOS:21 and 22, respectively. Those of skill can identify other such splice variants using

programs designed to identify splice variants such as the "Genefinder", "Genehunt" or "GRAIL"

programs available from CMS Molecular Biology.

IN THE CLAIMS:

Please cancel claims 72-76 without prejudice or disclaimer.

Please add the following new claims: